CarsonAllaria Wealth Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

CarsonAllaria Wealth Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-104	Closed	-$328	–	415
2023 Q2	$328	Hold	104	–	–	﹤0.01%	377
2023 Q1	$278	Hold	104	–	–	﹤0.01%	363
2022 Q4	$0	Sell	104 -58	-36%	-$252	﹤0.01%	372
2022 Q3	$1K	Sell	162 -1	-0.6%	-$8	﹤0.01%	329
2022 Q2	$2K	Hold	163	–	–	﹤0.01%	292
2022 Q1	$2K	Hold	163	–	–	﹤0.01%	310
2021 Q4	$5K	Buy	+163	New	+$6.6K	﹤0.01%	276

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

CarsonAllaria Wealth Management's SYRS Position: Q3 2023 in Review

CarsonAllaria Wealth Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2023, closing a stake of 104 shares — an estimated $328 sold.

CarsonAllaria Wealth Management first reported a position in SYRS in Q4 2021 and held it in 7 quarters. The position peaked at $5K in Q4 2021. 48 funds tracked by Wall St. Rank hold SYRS as of Q3 2023.

CarsonAllaria Wealth Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
CarsonAllaria Wealth Management sold 104 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $328.
CarsonAllaria Wealth Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
CarsonAllaria Wealth Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5K in Q4 2021.
48 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2023, filed 9 Nov 2023.